These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12046640)

  • 1. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.
    Gerlach J
    Ann Clin Psychiatry; 2002 Mar; 14(1):47-57. PubMed ID: 12046640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of newer antipsychotics on extrapyramidal function.
    Tarsy D; Baldessarini RJ; Tarazi FI
    CNS Drugs; 2002; 16(1):23-45. PubMed ID: 11772117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choosing an atypical antipsychotic.
    Sussman N
    Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Kissling W; Davis JM; Leucht S
    Schizophr Bull; 2012 Jan; 38(1):167-77. PubMed ID: 20513652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ
    J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
    Gao K; Kemp DE; Ganocy SJ; Gajwani P; Xia G; Calabrese JR
    J Clin Psychopharmacol; 2008 Apr; 28(2):203-9. PubMed ID: 18344731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the CATIE trial on treatment: extrapyramidal symptoms.
    Casey DE
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):25-31. PubMed ID: 16816797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
    Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
    J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability: how do newer generation "atypical" antipsychotics compare?
    Tandon R
    Psychiatr Q; 2002; 73(4):297-311. PubMed ID: 12418358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of atypical antipsychotics in the management of schizophrenia.
    Campbell M; Young PI; Bateman DN; Smith JM; Thomas SH
    Br J Clin Pharmacol; 1999 Jan; 47(1):13-22. PubMed ID: 10073734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.